Interviews

Arvind Trindade, MD, discusses the background of a study investigating rates of pancreatic and colon cancer among younger patients.

Hannah Abrams, MD, discusses the key takeaways of research into nonmedical barriers to HCT and CAR T therapy.

Hannah Abrams, MD, discusses the background behind research into nonmedical barriers to cell transplant and CAR T therapy.

Mark Litzow, MD, discusses the challenges of using immunotherapy for the treatment of acute lymphoblastic leukemia.

Alexander Kenigsberg, MD, discusses a new nonsurgical, robotic-focused ultrasound procedure for prostate cancer.

Paolo Ghia, MD, discusses the implications of the long-term follow-up of the CAPTIVATE trial investigating ibrutinib and venetoclax in CLL.

Enriqueta Felip, MD, PhD, discusses the 3475A-D77 trial of subcutaneous pembrolizumab vs intravenous pembrolizumab plus chemotherapy in metastatic NSCLC.

Hany Elmariah, MD, discusses how he sees fedratinib fitting into clincal practice for the treatment of myeloproliferative neoplasms.

Anthony S. Stein, MD, discusses a study of total marrow and lymphoid irradiation 20 Gy and post-transplant cyclophosphamide in acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.

Jeffrey Wong, MD, discusses the evolving field of combination therapy with radiopharmaceuticals in prostate cancer.

Natasha Leighl, MD, MMSc, BSc, discussed key findings from the PALOMA-3 trial for a community oncologist audience.

Jeffrey Wong, MD, discusses the unmet needs in prostate cancer treatment, especially in regard to radiopharmaceuticals.

Francis P. Worden, MD, discusses his key takeaways for other oncologists treating patients with radioidine-refractory differentiated thyroid cancer.

Hany Elmariah, MD, discusses incorporating fedratinib as maintenance therapy in the posttransplant setting to prevent relapse of MPNs and graft-vs-host disease.

Hany Elmariah, MD, discusses dose-limiting toxicities of fedratinib in a phase 1 study exploring the drug in patients with myeloproliferative neoplasms after HCT.

Jeff Auletta, MD, discusses the background, methods, design and findings from the ACCESS trial.

Geoffrey Shouse, DO, PhD, discusses what motivated this retrospective review of bispecific antibodies in diffuse large B-cell lymphoma at City of Hope.

Jared Weiss, MD, discussed the mechanism of action of JNJ-1900 and the preliminary data presented at the 2025 European Lung Cancer Congress.

Enriqueta Felip, MD, PhD, discusses the design of the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab in metastatic NSCLC.

Nicolas Ferreyros discusses the Community Oncology Alliance’s position statements on biomarker testing and physician autonomy.

Nicolas Ferreyros discussed central ideas from the Community Oncology Alliance to optimize cancer care in community oncology settings.

Marc Raab, MD, PhD, discussed the MajesTEC-5 trial of teclistamab plus standard myeloma therapies in transplant-eligible newly diagnosed multiple myeloma.

Jennifer Chan, MD, MPH, discussed outcomes of treating neuroendocrine tumors (NETs) with cabozantinib depending on whether they were pancreatic NETs or extrapancreatic NETs.

Yago Nieto, MD, PhD, discusses AFM13, how it works, and its effect as a bispecific antibody that targets CD30 and CD16.

John L. Marshall, MD, discusses the sequencing of targeted therapy for refractory metastatic colorectal cancer.

Julie Gralow, MD, FACP, FASCO, discusses the strategies and policy changes implemented by ASCO to address the oncology workforce shortage.

Cedric Pobel, MD, discusses how the results of the PEACE-1 trial support the use of radiotherapy plus standard of care and abiraterone in low-volume metastatic castration-sensitive prostate cancer.

Jeff Auletta, MD, discussed the ACCESS trial and explained that mismatched unrelated donor transplants can be a viable option.